Notably, 5 of 19 poor prognosis AML patients achieved complete remission (CR) after haploidentical NK cell therapy, with a significantly higher rate when KIR ligand mismatched donors were used. This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.